BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE

被引:0
|
作者
KITAGAWA, M
OKABE, T
OGINO, H
MATSUMOTO, H
SUZUKITAKAHASHI, I
KOKUBO, T
HIGASHI, H
SAITOH, S
TAYA, Y
YASUDA, H
OHBA, Y
NISHIMURA, S
TANAKA, N
OKUYAMA, A
机构
[1] MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN
[2] NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN
[3] KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.
引用
收藏
页码:2425 / 2432
页数:8
相关论文
共 50 条
  • [11] Cdk2 and Cdk4 cooperatively control the expression of Cdc2
    Berthet, Cyril
    Kaldis, Philipp
    CELL DIVISION, 2006, 1 (1)
  • [12] Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
    Meijer, L
    Borgne, A
    Mulner, O
    Chong, JPJ
    Blow, JJ
    Inagaki, N
    Inagaki, M
    Delcros, JG
    Moulinoux, JP
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 527 - 536
  • [13] Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
    Meijer, L.
    Borgne, A.
    Mulner, O.
    Chong, J. P. J.
    European Journal of Biochemistry, 243 (1-2):
  • [14] Amplified CDK2 and cdc2 activities in primary colorectal carcinoma
    Kim, JH
    Kang, MJ
    Park, CU
    Kwak, HJ
    Hwang, Y
    Koh, GY
    CANCER, 1999, 85 (03) : 546 - 553
  • [15] EFFECTS OF PHOSPHORYLATION BY CAK ON CYCLIN BINDING BY CDC2 AND CDK2
    DESAI, D
    WESSLING, HC
    FISHER, RP
    MORGAN, DO
    MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (01) : 345 - 350
  • [16] PHOSPHORYLATION AND ACTIVATION OF THE XENOPUS CDC25 PHOSPHATASE IN THE ABSENCE OF CDC2 AND CDK2 KINASE-ACTIVITY
    IZUMI, T
    MALLER, JL
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 (02) : 215 - 226
  • [17] RECONSTITUTION OF CYCLIN-DEPENDENT CDC2 AND CDK2 KINASE-ACTIVITIES IN-VITRO
    PAN, ZQ
    HURWITZ, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (27) : 20433 - 20442
  • [18] CDK2 ENCODES A CYCLIN-A ASSOCIATED PROTEIN-KINASE HOMOLOG OF CDC2 AND IS EXPRESSED EARLIER IN THE CELL-CYCLE THAN IS CDC2
    HARPER, JW
    RICHMAN, R
    HALL, FL
    WILLIAMS, RT
    LODGSON, N
    ELLEDGE, SJ
    FASEB JOURNAL, 1992, 6 (01): : A39 - A39
  • [19] Cell cycle sibling rivalry - Cdc2 vs. Cdk2
    Kaldis, P
    Aleem, E
    CELL CYCLE, 2005, 4 (11) : 1491 - 1494
  • [20] Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma
    Li, KKW
    Ng, IOL
    Fan, ST
    Albrecht, JH
    Yamashita, K
    Poon, RYC
    LIVER, 2002, 22 (03): : 259 - 268